AstraZeneca's potential relocation of vaccine production is a significant corporate decision that could impact its operational costs and strategic positioning. The reduced state support from the UK government is a critical factor in this decision, highlighting the importance of government incentives in corporate location decisions. However, the immediate stock price impact is neutral as the decision is not final and negotiations are ongoing.